Traders assign a 91% probability to no new COVID variant of concern before 2027 because global surveillance by the WHO and ECDC shows no strains currently meeting VOC criteria, with all active lineages classified as variants under monitoring or subvariants of Omicron. Recent developments reinforce this view: BA.3.2 (nicknamed Cicada) and others like XFG and NB.1.8.1 have spread in wastewater and limited sequences across multiple countries since late 2025, yet show no consistent evidence of substantially higher transmissibility, severity, or immune escape that would trigger a new designation. Widespread population immunity from prior infections and updated vaccines continues to limit severe outcomes, while genomic monitoring detects changes quickly without identifying disruptive shifts. With only months left in 2026, an unexpected emergence would require rapid escalation beyond observed patterns to alter the market's strong consensus.